Age-dependent changes in heparan sulfate in human Bruch's membrane: Implications for age-related macular degeneration

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 8, 2014, Pages 5370-5379

  Keenan, Tiarnan D L ^a,b,c,d   Pickford, Claire E ^a   Holley, Rebecca J ^a,d   Clark, Simon J ^a,b   Lin, Wanchang ^a,b   Dowsey, Andrew W ^a,b   Merry, Catherine L ^a   Day, Anthony J ^d   Bishop, Paul N ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

AMD; Bruch's membrane; Heparan sulfate

Indexed keywords

2 AMINOACRIDONE; ACRIDONE DERIVATIVE; COMPLEMENT FACTOR H; HEPARAN SULFATE; HEPARANASE; HEPARIN LYASE; PRONASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BINDING SITE; BRUCH MEMBRANE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TISSUE PREPARATION; VERY ELDERLY;

AMD; BRUCH'S MEMBRANE; HEPARAN SULFATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BRUCH MEMBRANE; CADAVER; CHROMATOGRAPHY, REVERSE-PHASE; FEMALE; HEPARITIN SULFATE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; POLYSACCHARIDE-LYASES; RETINA;

EID: 84907621306     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14126     Document Type: Article

References (60)

1. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond). 2008;22:905-911.
3. Day AJ, Clark SJ, Bishop PN. Understanding the molecular basis of age-related macular degeneration and how the identification of new mechanisms may aid the development of novel therapies. Exp Rev Ophthalmol. 2011;6:123-128.
4. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010; 29:95-112.
5. Langford-Smith A, Keenan TD, Clark SJ, Bishop PN, Day AJ. The role of complement in age-related macular degeneration: heparan sulphate, a ZIP code for complement factor H. J Innate Immun. 2014;6:407-416.
6. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-7232.
7. Edwards AO, Ritter R III, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
8. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389.
9. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421.
10. Hageman GS, Hancox LS, Taiber AJ, et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. 2006;38:592-604.
11. Fritsche LG, Chen W, Schu M, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45: 433-439.
12. Seddon JM, Yu Y, Miller EC, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet. 2013;45:1366-1370.
13. Sofat R, Casas JP, Webster AR, et al. Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol. 2012;41:250-262.
14. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immunemediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20:705-732.
15. Crabb JW, Miyagi M, Gu X, et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99:14682-14687.
16. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-152.
17. Skeie JM, Fingert JH, Russell SR, Stone EM, Mullins RF. Complement component C5a activates ICAM-1 expression on human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 2010;51:5336-5342.
18. Gerl VB, Bohl J, Pitz S, et al. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43: 1104-1108.
19. Mullins RF, Johnson MN, Faidley EA, Skeie JM, Huang J. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:1606-1612.
20. Seth A, Cui J, To E, Kwee M, Matsubara J. Complementassociated deposits in the human retina. Invest Ophthalmol Vis Sci. 2008;49:743-750.
21. Mullins RF, Dewald AD, Streb LM, et al. Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. Exp Eye Res. 2011;93:565-567.
22. Clark SJ, Perveen R, Hakobyan S, et al. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. J Biol Chem. 2010;285:30192-30202.
23. Clark SJ, Ridge LA, Herbert AP, et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol. 2013;190:2049-2057.
24. Clark SJ, Higman VA, Mulloy B, et al. His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-diseaseassociated form. J Biol Chem. 2006;281:24713-24720.
25. Prosser BE, Johnson S, Roversi P, et al. Structural basis for complement factor H linked age-related macular degeneration. J Exp Med. 2007;204:2277-2283.
26. Mullins, RF, Sohn EH. Bruch's membrane: the critical boundary in macular degeneration. In: Yind DG-S, ed. Age Related Macular Degeneration-The Recent Advances in Basic Research and Clinical Care. Rijeka, Croatia: InTech; 2012.
27. Booij JC, Baas DC, Beisekeeva J, Gorgels TG, Bergen AA. The dynamic nature of Bruch's membrane. Prog Retin Eye Res. 2010;29:1-18.
28. Clark SJ, Bishop PN, Day AJ. Complement factor H and agerelated macular degeneration: the role of glycosaminoglycan recognition in disease pathology. Biochem Soc Trans. 2010; 38:1342-1348.
29. Kreuger J, Kjellen L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem. 2012;60:898-907.
30. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 2010; 339:237-246.
31. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010;277:3904-3923.
32. Keenan TD, Clark SJ, Unwin RD, et al. Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci. 2012; 53:7528-7538.
33. Lindahl U, Li JP. Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol. 2009;276:105-159.
34. Clark SJ, Keenan TD, Fielder HL, et al. Mapping the differential distribution of glycosaminoglycans in the adult human retina, choroid, and sclera. Invest Ophthalmol Vis Sci. 2011;52:6511-6521.
35. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011;37:a004952.
36. Clark SJ, Bishop PN, Day AJ. The proteoglycan glycomatrix: a sugar microenvironment essential for complement regulation. Front Immunol. 2013;4:412.
37. Park PJ, Shukla D. Role of heparan sulfate in ocular diseases. Exp Eye Res. 2013;110:1-9.
38. Bruinsma IB, te Riet L, Gevers T, et al. Sulfation of heparan sulfate associated with amyloid-beta plaques in patients with Alzheimer's disease. Acta Neuropathol. 2010;119:211-220.
39. Ohno-Matsui K. Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res. 2011;30:217-238.
40. Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M. Age-related macular degeneration (AMD): Alzheimer's disease in the eye? J Alzheimers Dis. 2011;24:615-631.
41. Raman K, Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. Curr Chem Biol. 2010;4:20-31.
42. Blackhall FH, Merry CL, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer. 2001;85:1094-1098.
43. Holley RJ, Deligny A, Wei W, et al. Mucopolysaccharidosis type I, unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking alpha-liduronidase. J Biol Chem. 2011;286:37515-37524.
44. Deakin JA, Lyon M. A simplified and sensitive fluorescent method for disaccharide analysis of both heparan sulfate and chondroitin/dermatan sulfates from biological samples. Glycobiology. 2008;18:483-491.
45. Filzmoser P, Hron K, Reimann C. Univariate statistical analysis of environmental (compositional) data: problems and possibilities. Sci Total Environ. 2009;407:6100-6108.
46. Bland JM, Altman DG. Transforming data. BMJ. 1996;312:770.
47. Feng C, Wang H, Lu N, Tu XM. Log transformation: application and interpretation in biomedical research. Stat Med. 2013;32: 230-239.
48. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 1992;119:961-975.
49. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci. 2004;117:2249-2258.
50. Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35: 2857-2864.
51. Okubo A, Rosa RH Jr, Bunce CV, et al. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci. 1999;40:443-449.
52. Karampelas M, Sim DA, Keane PA, et al. Evaluation of retinal pigment epithelium-Bruch's membrane complex thickness in dry age-related macular degeneration using optical coherence tomography. Br J Ophthalmol. 2013;97:1256-1261.
53. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102:823-828.
54. Kliffen M, Mooy CM, Luider TM, et al. Identification of glycosaminoglycans in age-related macular deposits. Arch Ophthalmol. 1996;114:1009-1014.
55. Lindahl B, Eriksson L, Lindahl U. Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. Biochem J. 1995;306:177-184.
56. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem. 1994;269:18881-18890.
57. Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M. Agedependent modulation of heparan sulfate structure and function. J Biol Chem. 1998;273:13395-13398.
58. Williamson KA, Hamilton A, Reynolds JA, et al. Age-related impairment of endothelial progenitor cell migration correlates with structural alterations of heparan sulfate proteoglycans. Aging Cell. 2013;12:139-147.
59. Garland DL, Fernandez-Godino R, Kaur I, et al. Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Hum Mol Genet. 2014;23:52-68.
60. Kelly U, Yu L, Kumar P, et al. Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration. J Immunol. 2010;185:5486-5494.